BofA raised the firm’s price target on Cytokinetics (CYTK) to $62 from $56 and keeps a Neutral rating on the shares. After incorporating the latest feedback from key opinion leaders, the firm is “modestly” increasing its aficamten forecasts, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ Aficamten Faces Competitive and Regulatory Challenges: Hold Rating Maintained
- Verisign, HEICO, Transdigm, Albertsons, Cytokinetics: Insider Moves Unveiled!
- Cytokinetics price target raised to $82 from $71 at Barclays
- Cytokinetics price target raised to $56 from $52 at BofA
- Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook